Compare Neurocrine Biosciences Inc (NBIX) vs Yum! Brands, Inc. (YUM) Price & Performance

Neurocrine Biosciences IncTrade

Yum! Brands, Inc.Trade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Yum! Brands, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Yum! Brands, Inc. trades at $148 (market cap $40.62B). The key difference: Yum! Brands, Inc. is far larger — about 2.3× Neurocrine Biosciences Inc's market cap, and Yum! Brands, Inc. pays a 2.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	NBIX	YUM
Market Cap	$17.40B	$40.62B
Sector	Health	Consumer Cyclical
52-Week High	$180.55	$168.16
52-Week Low	$123.10	$138.21
Enterprise Value	$16.49B	$51.88B
Dividend Yield	—	2.04%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Yum! Brands, Inc.

YUM trades at $147.10, down 0.55% amid a cyclosporiasis outbreak linked to Taco Bell lettuce. Technicals are bearish with key support at $145, while fundamentals show steady revenue growth to $8.21B in 2025 and a net margin of 20.48%. The company maintains strong cash flow from operations of $2.01B but carries high long-term debt of $11.25B.

Despite near-term headwinds from food safety concerns, YUM's diversified brand portfolio and consistent profitability support a positive long-term outlook. Analyst consensus price target of $177 suggests 20% upside, but investors should monitor outbreak resolution and Q2 2026 earnings due soon.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 7 hours agoBullish View details →

YUM

Yum! Brands faces cyclosporiasis outbreak but impact is mild with no deaths and ongoing recalls.Seeking Alpha · 16 hours agoBearish Taylor Farms recalls iceberg lettuce in 27 states over Cyclospora contamination riskCNBC · 3 days agoBearish Sweetgreen stock jumps 15% after diarrhea outbreak traced to Taco Bell, not salad chainNew York Post · 4 days agoNeutral View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Yum! Brands, Inc.

Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.